## **Core Concept**
Multibacillary leprosy, a more severe form of leprosy, requires prolonged treatment and rigorous follow-up due to its potential for complications and disabilities. The World Health Organization (WHO) recommends multidrug therapy (MDT) for multibacillary leprosy, which includes rifampicin, clofazimine, and dapsone. Post-treatment follow-up is crucial for early detection of relapse and management of complications.

## **Why the Correct Answer is Right**
The correct answer, **5 years**, is based on the WHO's guidelines for post-treatment follow-up in multibacillary leprosy. Patients who have completed treatment for multibacillary leprosy should be followed up for at least 5 years to detect any possible relapse early. This duration is chosen because most relapses occur within 5 years after completion of treatment. Regular follow-up allows for the early detection of relapse, which is critical for preventing further nerve damage and disability.

## **Why Each Wrong Option is Incorrect**
- **Option A: 1 year** - This duration is considered too short for adequate follow-up in multibacillary leprosy, as it does not capture the risk of late relapses.
- **Option B: 2 years** - Similarly, 2 years is still within the early period post-treatment and does not fully align with the recommended duration for monitoring for potential relapses.
- **Option C: 10 years** - Although prolonged follow-up might seem beneficial, 10 years is generally not recommended as the standard follow-up period for all patients with multibacillary leprosy; 5 years is considered sufficient for most cases.

## **Clinical Pearl / High-Yield Fact**
A crucial point to remember is that after completing multidrug therapy for multibacillary leprosy, patients should be monitored for signs of relapse, such as new skin lesions, nerve damage, or increased bacillary load, for at least **5 years**. Early detection of relapse significantly improves outcomes and prevents long-term disability.

## **Correct Answer:** D. 5 years.